Asuragen
The company’s research-use-only AmplideX Nanopore Carrier Plus kit can interrogate 11 genes underpinning nine common carrier screening conditions.
Bio-Techne Receives IVDR Certification for Chronic Myeloid Leukemia Test
The qPCR-based test quantifies BCR-ABL1 and ABL1 transcripts in blood samples from patients with chronic myeloid leukemia to determine their response to treatment.
Oxford Nanopore Technologies, Bio-Techne Partner to Develop Carrier Screening Assay
The project will leverage Asuragen's long-range PCR and Oxford Nanopore's sequencing capabilities to develop a sequencing workflow for carrier screening.
Thermo Fisher Scientific Deal Expands Possibilities for Exosome Dx Business, Bio-Techne CEO Says
Premium
The deal with Thermo Fisher is for the development of Bio-Techne's second test in its Exosome Diagnostics portfolio, a multigene assay for kidney transplant rejection.
Bio-Techne expects the acquisition will provide it with a basis to build out its IVD presence, given Asuragen's diagnostic tests and regulatory expertise.